Penumbra, Inc. to Participate in CEO Discussion with Bank of America
Penumbra, Inc. (NYSE: PEN) has announced that its CEO will participate in a discussion with Bank of America on December 8, 2020, at 8:30 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Penumbra, Inc. (NYSE: PEN) has announced that its CEO will participate in a discussion with Bank of America on December 8, 2020, at 8:30 AM ET. The event will focus on the company's innovative healthcare therapies. An audio webcast will be accessible on the company’s website for at least two weeks post-event. Based in Alameda, California, Penumbra specializes in developing and marketing products addressing significant medical needs in healthcare markets worldwide.
Details
News Market Reaction – PEN
The recorded move for PEN in the trading session of this news was +6.73%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALAMEDA, Calif., Dec. 4, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its chief executive officer is scheduled to participate in a discussion with Bank of America on Tuesday, December 8, 2020.
Event: CEO Discussion with Bank of America
Date: Tuesday, December 8, 2020
Time: 8:30am ET / 5:30am PT
An audio webcast of the discussion will be available by visiting the investors' section of the company's website at www.penumbrainc.com. The audio webcast will be available on the company's website for at least two weeks following the event.
About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra sells its products to hospitals and healthcare providers primarily through its direct sales organization in the United States, most of Europe, Canada and Australia, and through distributors in select international markets. The Penumbra logo is a trademark of Penumbra, Inc. For more information, visit www.penumbrainc.com.
Investor Relations
Penumbra, Inc.
510-995-2461
investors@penumbrainc.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/penumbra-inc-to-participate-in-ceo-discussion-with-bank-of-america-301186771.html
SOURCE Penumbra, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.